Loading…
Cytosorbents Corporation is projected to rise to $0.5525 by 2027, a +12% move from its current price of $0.4923. CTSO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4762 | $0.4924 | $0.5092 | +0.02% |
| May 30 | $0.4697 | $0.4925 | $0.5164 | +0.05% |
| May 31 | $0.4649 | $0.4926 | $0.5221 | +0.07% |
| Jun 1 | $0.4608 | $0.4928 | $0.5269 | +0.09% |
| Jun 2 | $0.4573 | $0.4929 | $0.5312 | +0.12% |
| Jun 3 | $0.4541 | $0.493 | $0.5352 | +0.14% |
| Jun 4 | $0.4513 | $0.4931 | $0.5388 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4513 | $0.4931 | $0.5388 | +0.16% |
| Week 2 | $0.4357 | $0.4939 | $0.5599 | +0.32% |
| Week 3 | $0.4243 | $0.4947 | $0.5768 | +0.49% |
| Week 4 | $0.415 | $0.4955 | $0.5916 | +0.65% |
| Week 5 | $0.4071 | $0.4963 | $0.6051 | +0.81% |
| Week 6 | $0.4001 | $0.4971 | $0.6177 | +0.98% |
| Week 7 | $0.3938 | $0.4979 | $0.6295 | +1.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytosorbents Corporation is a healthcare company that engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge designed to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, ECOS-300CY to reduce cytokines and other inflammatory mediators in an ex vivo organ perfusion system, VetResQ for animal applications, and PuriFi for blood purification therapies.
Cytosorbents was founded in 1997 and is headquartered in Princeton, New Jersey.
CTSO is currently trading at $0.4608 per share, with a market capitalization of $28.94M and a rank of 4819. These metrics place the stock among smaller-market healthcare names with a focus on blood purification technology. The price outlook varies across the forecast, with growth potential emerging over the multi-year horizon as shown by the year-by-year projections.
A major floor 31.5% below — a decisive break under it would weaken the trend.
The nearest floor, 6.6% below — buyers have tended to step in here.
The nearest ceiling, 34.1% above — a clean break opens room to run.
A major ceiling 64.5% above — clearing it would confirm fresh momentum.
Key CTSO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTSO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4692 | Buy | $0.4785 | Buy |
| MA 10 | $0.4909 | Buy | $0.497 | Sell |
| MA 20 | $0.55 | Sell | $0.5315 | Sell |
| MA 50 | $0.5914 | Sell | $0.5853 | Sell |
| MA 100 | $0.6422 | Sell | $0.638 | Sell |
| MA 200 | $0.7423 | Sell | $0.7242 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.81 | Neutral |
| Stoch RSI (14) | 38.89 | Neutral |
| CCI (20) | -63.17 | Neutral |
| Williams %R (14) | -81.18 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -19.21 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 18.82 | Buy |
| TRIX (15) | -0.78 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 41.80 | Neutral |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.46 | Buy |
| ADX (14) | 22.87 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture conveys a neutral stance, with RSI14 at 30 indicating potential oversold conditions. Nearby moving averages show SMA50 at $0.5995 and SMA200 at $0.747, suggesting near-term resistance relative to the current price. Support is listed at $0.46, with a resistance level at $0.66.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.46 | $0.4923 | $0.6586 | 0% | Neutral | |
| $0.4286 | $0.5525 | $0.7601 | +12% | Neutral | |
| $0.5092 | $0.6793 | $0.975 | +38% | Bullish | |
| $0.5404 | $0.742 | $1.10 | +51% | Bullish | |
| $0.5061 | $0.713 | $1.09 | +45% | Bullish | |
| $0.5385 | $0.7767 | $1.21 | +58% | Bullish | |
| $0.505 | $0.7446 | $1.19 | +51% | Bullish | |
| $0.4783 | $0.7203 | $1.17 | +46% | Bullish | |
| $0.6442 | $0.9896 | $1.64 | +101% | Bullish | |
| $0.6948 | $1.09 | $1.84 | +121% | Bullish | |
| $0.7723 | $1.32 | $2.39 | +168% | Bullish | |
| $1.21 | $2.42 | $4.86 | +392% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.46 | $0.4923 | $0.5771 | +0.00% |
| June 2026 | $0.4108 | $0.4848 | $0.5876 | -1.51% |
| July 2026 | $0.4216 | $0.5028 | $0.6194 | +3.70% |
| August 2026 | $0.4173 | $0.5017 | $0.6258 | -0.23% |
| September 2026 | $0.3988 | $0.4827 | $0.6083 | -3.78% |
| October 2026 | $0.4041 | $0.4922 | $0.626 | +1.97% |
| November 2026 | $0.4206 | $0.5151 | $0.6604 | +4.65% |
| December 2026 | $0.4141 | $0.5098 | $0.6586 | -1.03% |
Click any year to see its month-by-month CTSO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CTSO could reach as high as $0.6586, with a base case around $0.4923 and support toward $0.46 — roughly 0% from $0.4923. Price action looks broadly range-bound.
Expect CTSO to range from $0.4286 to $0.7601 through 2027. The $0.5525 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
The CTSO price prediction for 2028 points to an average of $0.6793 (low $0.5092, high $0.975) — a potential gain of +38% on today's $0.4923. Momentum favours further upside here.
In 2029, CTSO is projected to trade between $0.5404 and $1.10, averaging $0.742 — a potential gain of +51% from today's $0.4923. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Cytosorbents Corporation's 2030 outlook centres on $0.713, within a $0.5061 to $1.09 range. That is -4% versus the projected 2029 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2031, CTSO could reach as high as $1.21, with a base case around $0.7767 and support toward $0.5385 — roughly +58% from $0.4923. Buyers look set to stay in control over this stretch.
Expect CTSO to range from $0.505 to $1.19 through 2032. The $0.7446 average target implies a +51% move from current prices. That is -4% versus the projected 2031 average. Momentum favours further upside here.
The CTSO price prediction for 2033 points to an average of $0.7203 (low $0.4783, high $1.17) — a potential gain of +46% on today's $0.4923. Buyers look set to stay in control over this stretch.
In 2034, CTSO is projected to trade between $0.6442 and $1.64, averaging $0.9896 — a potential gain of +101% from today's $0.4923. That is up +37% on the projected 2033 average. Momentum favours further upside here.
Cytosorbents Corporation's 2035 outlook centres on $1.09, within a $0.6948 to $1.84 range. That is up +10% on the projected 2034 average. That marks a +121% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CTSO could reach as high as $2.39, with a base case around $1.32 and support toward $0.7723 — roughly +168% from $0.4923. Momentum favours further upside here.
Expect CTSO to range from $1.21 to $4.86 through 2050. The $2.42 average target implies a +392% move from current prices. That is up +83% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CTSO today (≈ 2,031.281739 CTSO) could be worth
$4,919.6
+$3,919.6 (+392%) by 2050 · US Dollar
Based on the average projected CTSO price of $2.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTSOwould be worth at today's price.
$1,000 invested in CTSO on May 27, 2025 (≈ 1,218.026826 CTSO) would be worth
$599.63
-$400.37 (-40.0%) today · 0.60× · US Dollar
Based on a CTSO entry price of $0.821 vs. today's $0.4923.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.47 | $1,047.45 | +4.7% |
| 1 month ago | $0.612 | $804.41 | -19.6% |
| 3 months ago | $0.727 | $677.17 | -32.3% |
| 6 months ago | $0.811 | $607.03 | -39.3% |
| 1 year ago | $0.821 | $599.63 | -40.0% |
| All time (5.0y) ago | $7.98 | $61.69 | -93.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTSO forecast.
Our base-case forecast reaches $0.98 around 2034.
Implied market cap at $0.98: $61.54M
Longer-horizon forecasts point to an overall bullish trajectory after 2026. In 2026 the average price is $0.4608 with a current-like min of $0.46 and a max of $0.6058, and no projected ROI. By 2028 the average rises to $0.606, then to $0.6597 in 2029, with ROIs of 31.5% and 43.2% respectively.
The 2030 forecast shows an average of $0.6395 and a max of $0.9724, with an 38.8% ROI and a bullish sentiment. The outlook strengthens into 2031–2035, with 2031 average $0.686 and max $1.07 (ROI 48.9%), 2032 average $0.6482, 2033 average $0.6262, 2034 average $0.8441 (ROI 83.2%), and 2035 average $0.9263 (ROI 101%). By 2040 the average is projected at $1.10 with a max of $1.98 (ROI 138.5%), and by 2050 the average reaches $2.01 with a max of $4.00 (ROI 335.8%).
These figures reflect bullish momentum in the later years, but they are estimates and not guarantees. The forecast includes a clear upward path in average prices and sizable potential upside, tempered by notable volatility (annualized volatility of 60%).
Tap a question to reveal the answer.
2030 Avg: $0.6395; Min: $0.4555; Max: $0.9724; ROI: 38.8%; Sentiment: BULLISH.
Forecasts show a path toward higher averages and bullish sentiment after 2026, with 2028 Avg $0.606, 2029 Avg $0.6597, and rising ROIs up to 335.8% by 2050, though these are estimates and not guarantees.
Yes. The 2031 max is $1.07, 2034 max $1.40, 2035 max $1.56, 2040 max $1.98, and 2050 max $4.00, indicating potential upside across several future years.
Current price is $0.4608 with a market cap of $28.94M and a rank of 4819.
RSI14 is 30 (neutral/oversold), SMA50 is $0.5995, SMA200 is $0.747, with support at $0.46 and resistance at $0.66; the 30-day range is $0.3708–$0.5726.
Cytosorbents Corporation Community Discussion
0Share your Cytosorbents Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.